Using Basic Science to Design a Clinical Trial: Baseline Characteristics of Women Enrolled in the Kronos Early Estrogen Prevention Study (KEEPS) by Miller, V. M. et al.
Using Basic Science to Design a Clinical Trial: Baseline
Characteristics of Women Enrolled in the Kronos Early
Estrogen Prevention Study (KEEPS)
V. M. Miller & D. M. Black & E. A. Brinton &
M. J. Budoff & M. I. Cedars & H. N. Hodis & R. A. Lobo &
J. E. Manson & G. R. Merriam & F. Naftolin &
N. Santoro & H. S. Taylor & S. M. Harman
Received: 6 March 2009 /Accepted: 27 April 2009 /Published online: 22 May 2009
# The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract Observational and epidemiological studies sug-
gest that menopausal hormone therapy (MHT) reduces
cardiovascular disease (CVD) risk. However, results from
prospective trials showed neutral or adverse effects most
likely due to differences in participant demographics, such
as age, timing of initiation of treatment, and preexisting
cardiovascular disease, which reflected in part the lack of
basic science information on mechanisms of action of
hormones on the vasculature at the time clinical trials were
designed. The Kronos Early Estrogen Replacement Study
(KEEPS) is a prospective, randomized, controlled trial
designed, using findings from basic science studies, to test
the hypothesis that MHT when initiated early in menopause
reduces progression of atherosclerosis. KEEPS participants
are younger, healthier, and within 3 years of menopause thus
matching more closely demographics of women in prior
observational andepidemiologicalstudies thanwomeninthe
Women’s Health Initiative hormone trials. KEEPS will
provide information relevant to the critical timing hypothesis
for MHT use in reducing risk for CVD.
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Chronic diseases potentially affected by menopausal hor-
mone treatment (MHT) include cardiovascular disease
(CVD; which includes all atherosclerotic disease such as
coronary heart disease (CHD) and stroke), osteoporosis,
venous thromboembolic disease and cancers of the breast,
endometrium, and colon. These diseases constitute the most
common sources of morbidity and mortality among women
and cost scores of billions of dollars annually. Of these,
CVD remains the single greatest killer of women, account-
ing for approximately 40% of total mortality vs. about 5%
for breast cancer [62]. Over the last decade, controversies
regarding benefits, risks, and appropriate use of MHT to
prevent cardiovascular disease have flared when emerging
clinical trial evidence appeared to be at odds with well-
established observational and epidemiological data. This
paper provides a brief review of the historical perspective
behind the controversy surrounding the use and efficacy of
MHT for prevention of CVD and highlights the design and
demographics of an ongoing clinical trial designed to help
resolve this controversy, in particular, as to the timing
relative to menopause for initiation of treatment (critical
timing hypothesis).
Historical Considerations
Human Studies Over the past 30 years, numerous large
observational studies [9, 10, 24, 32, 34, 37, 84, 97] found
that MHT, in addition to reducing menopausal symptoms,
reduced both CVD incidence and all-cause mortality by
nearly one half in postmenopausal women. Furthermore,
MHT was reported in both observational studies and
randomized clinical trials to significantly reduce the risk
of osteoporosis-related fractures [12, 23, 65] and colon
cancer [27] while increasing age-adjusted incidence of
breast cancer by about 20% [6, 17, 76], but decreasing
breast cancer mortality by over 20% [34]. Based on the
expectation of CVD protection, the benefit/risk ratio for
MHT was calculated to be positive for most women [16].
The biological plausibility of atheroprevention by MHT
is supported by a body of investigations demonstrating that
estrogens improve a variety of known and suspected risk
factors for atherosclerosis [44]. The Postmenopausal Estro-
gen/Progestin Interventions (PEPI) prospective trial, which
compared the use of conjugated equine estrogen (CEE)
alone and in three different CEE–progestin combinations
and placebo in 875 healthy postmenopausal women aged
45–64 years, showed increases in high-density lipoprotein
cholesterol (HDL-C) and decreases in low-density lipopro-
tein cholesterol (LDL-C) and fibrinogen in women receiv-
ing estrogen [91]. Subsequently, other studies have
confirmed favorable lipid effects, including lowering of
LDL-C and lipoprotein-a and raising of HDL-C levels [19,
28, 39, 53, 82].
Estrogenic effects on lipid profiles alone, however, were
considered unlikely to account for all of the evident
beneficial effects of estrogen which appeared to account
both for lower atherosclerosis rates in premenopausal
women vs. age-matched men and for the exponential
increase in cardiovascular risk in women associated with
the menopause-related decline in estrogen. However, in the
early 1990s when some of the results of these epidemio-
logical and observational studies were published, little was
known about potential nonlipid actions of estrogen on the
cardiovascular system.
However, recommendations were emerging from the
observational studies and the PEPI trial for the use of MHT
for women with coronary heart disease or at high risk for
coronary heart disease [29]. Following on the heels of these
recommendations, a major prospective clinical trial, the
Women’s Health Initiative (WHI), was designed in 1991
and initiated in 1992 to test whether MHT would provide
primary prevention for cardiovascular disease (i.e., reduc-
tion in the number of major cardiovascular events, heart
attacks, and strokes). The selection of hormonal treatments
(type and dose) for use in the WHI was based on the MHT
regimens reported most frequently prescribed in the USA
and which had been used in previous observational studies
and the PEPI trial: conjugated equine estrogen (0.625 mg/
day) plus medroxyprogesterone acetate (MPA; 2.5 mg/day),
or CEE alone in women without a uterus [35, 91].
In order to have sufficient statistical power to detect
significant differences in cardiovascular event rates within
the relatively short time frame of the trial, women across a
wide spectrum of ages from 50 to 79 years with the vast
majority of subjects older than 60 years were enrolled. In
addition, a secondary end point in WHI was bone density
for which there were few data available on effects of MHT
in older women. In order to minimize dropouts among
subjects randomized to placebo, women with severe
menopausal symptoms who could not tolerate a 3-month
washout period or might not tolerate randomization to
placebo were excluded. Thus, for reasons of study
practicality and statistical power, very few WHI subjects
were like the women in the observational studies because
observational data are based on clinical practice and in
typical clinical practice, MHT was initiated early in the
course of estrogen deficiency usually to treat menopausal
symptoms. Occasionally, MHT was initiated years after the
menopause. Women also were excluded from the WHI for
prior CVD events but only by self-report. While these
criteria were believed to be sufficient at the time of the trial,
many subjects had significant CVD risk and/or were found
to have had a prior CVD [35, 71].
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early in 2002 because accumulating data showed a trend
toward increased breast cancer which crossed a prespecified
stopping point; thus, the benefit/risk ratio for the treatment
was believed to have shifted from positive to negative [71].
Ironically, the effect on breast cancer was later found not to
be statistically significant, and early termination of the trial
rendered other findings similarly inconclusive. The CEE
alone portion of the WHI was also terminated early,
although this time for perceived lack of likelihood of
ultimate net benefit, again truncating data collection and
confounding interpretation of results. The key question
remaining to be answered is “What are the reasons for the
discrepancies in effects on cardiovascular protection among
observational studies and this major clinical trial?”
Animal Studies Clues to the answer to this question come as
a result of initiatives in the early 1990s from the National
Institutes of Health that encouraged research into basic
mechanisms of estrogen actions. The typical experimental
animal model used to investigate arterial actions of estrogen
was to remove ovaries from healthy adult animals. Follow-
ing ovariectomy, estrogen, usually 17β-estradiol, was
administered immediately or shortly after the procedure by
way of intramuscular injection or subcutaneous time-release
pellets or infusion minipumps. Thus, the timing of treatment
was similar to that of clinical practice, that is, to initiate
treatment around the time of estrogen deficiency.
In support of this concept, estrogen treatment consis-
tently reduced by 50–70% histologically defined coronary
artery atherosclerosis if treatment was initiated immediately
after ovariectomy in surgically menopausal (ovariecto-
mized) cynomolgus monkeys, which develop atheromatous
lesions similar to those in humans, but not if treatment was
delayed for 2 years [14].
In brief, these studies provided evidence to support
potentially beneficial arterial actions of estrogen, as was
suggested by observational studies in humans, including
reduced formation of atheroma lesions at sites of endothe-
lial injury, reduced blood pressure, and increased arterial
compliance, all actions which maintain arterial health.
Conversely, the absence of estrogen and/or related down-
regulation of estrogen receptors accelerates development of
atherosclerosis [1, 15, 52, 86–89, 92, 93, 95, 98].
Rationale for the Design of the Kronos Early Estrogen
Prevention Study
Thus, what has emerged from results of studies conducted
in experimental animals and what can be identified as a
critical difference between previous observational studies in
humans and the WHI hormone trials was the time for
initiation of treatment relative to menopause [43]. In
particular, the mean age of menopause in the USA is
51 years, which corresponds to the age of women in the
Nurses Health Study (NHS) who initiated MHT as in usual
clinical practice for menopausal symptoms in the perime-
nopause [31]. This age and timing of MHT initiation
contrasts with that of participants in the WHI who were an
average of 63 years of age at MHT initiation, approximately
12 years past menopause [46, 59]. Because atherosclerosis
progresses gradually before declaring itself with a clinical
event [60, 64], a significant number of women in the WHI
likely had subclinical atherosclerosis at randomization.
The presence of subclinical disease might have ac-
counted for the tendency for CVD events to be increased
early in the WHI, just as in the major secondary CVD
prevention study of MHT, the Heart and Estrogen/Progestin
Replacement Study (HERS) which began concurrently with
the WHI. The HERS showed that in women with preexist-
ing disease, there was an increase in CVD events in the first
year or two of the trial. Although continued use of MHT in
HERS was associated with a reversal of this trend, the
major conclusion from that trial, contrary to conclusions
drawn from meta-analyses of the literature [29] was that
women with preexisting CHD were not candidates for
preventive therapy with MHT [47]. This conclusion
changed clinical practice.
Analysis of the NHS and post hoc analysis of data from
the WHI based on timing of initiation of treatment relative
to menopause supports the concept that initiation of
treatment (up to 10 years after the menopause) reduces
risk of adverse cardiac events [33, 46, 59]. Furthermore, as
in the animal studies, MHTadministered to individuals with
established atherosclerosis did not induce regression of
established lesions [11, 38, 42, 47]. Collectively, these
studies suggest that MHT may provide primary prevention
for CVD in women by preventing or reducing (slowing)
early stages of atherogenic disease processes in the
immediate time of menopause when endogenous estrogen
shows the steepest decline [43]. Studies in humans, of
course, were disadvantaged by the inability to obtain
accurate histological assessment of disease progression,
and noninvasive techniques to monitor progression of the
atherosclerosis, such as B-mode ultrasound imaging of
carotid artery wall thickness and plaque or computer-based
tomography of coronary artery calcification, were not
widely available nor were they sufficiently validated in
1991 to be used as endpoints when the WHI was designed.
Advances in these technologies [30, 40] have prompted
their use in a small subgroup of the CEE only group of the
WHI at the end of the trial [58] and as the major endpoints
in ongoing trials of MHT (see below).
An important difference between studies conducted in
laboratory animals and clinical trials in humans is that most
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CEE but rather 17β-estradiol by a nonoral route. Therefore,
possible differences between efficacy and safety of complex
conjugated estrogen preparations and transdermal prepara-
tions of MHT on cardiovascular parameters remain to be
clarified [22, 66, 74, 75, 77].
From these historical considerations, two hypotheses
emerge which require rigorous testing in humans: (1) MHT
initiated early after menopause (i.e., prior to the appearance
of advanced atherosclerotic lesions) will prevent progres-
sion of atherosclerosis and (2) oral CEE and transdermal
17β-estradiol will be similarly efficacious in their arterial
effects. These hypotheses are the basis of the Kronos Early
Estrogen Prevention Study (KEEPS). Findings of the
KEEPS have the potential to affect the health of many
millions of women who may endure cardiac events and
bone fractures that could be prevented. If there proves to be
a window of time in the early postmenopause when
initiation of long-term MHT has a net beneficial effect,
then women can feel reassured that treatment of their
menopausal symptoms when they are likely to be the most
severe, can concurrently protect their vascular system, and
can reduce bone resorption.
KEEPS Methods
KEEPS was designed as a randomized, placebo-controlled,
double-blinded, prospective trial (KEEPS; NCT000154180)
to evaluate effects of MHT on progression of atherosclero-
sis as defined by carotid intima–media thickness (CIMT)
[44] and coronary arterial calcification (CAC) [8, 73]i n
women who more closely match the age of initiation of
MHT reported by prior observational studies. Women
meeting inclusion criteria subsequently were randomized
to daily placebo, oral CEE, or transdermal 17β-estradiol
with placebo or pulsed progesterone for 12 days/month.
The detailed inclusion and exclusion criteria for KEEPS
have been published elsewhere [36]. In brief, women
between the ages of 42 and 58 years of age who were at
least 6 months and no more than 36 months from their last
menses with plasma follicle-stimulating hormone (FSH)
level ≥35 ng/mL and/or E2 levels <40 pg/mL were eligible.
A history of clinical CVD including myocardial infarction,
angina, congestive heart failure, or thromboembolic disease
excluded women from KEEPS. Other major cardiovascular
risk factors excluding participation were current heavy
smoking (more than ten cigarettes/day by self-report),
morbid obesity [body mass index (BMI) >35 mm
2/kg],
dyslipidemia (LDL cholesterol >190 mg/dL), hypertrigly-
ceridemia (triglycerides >400 mg/dL), and uncontrolled
hypertension (systolic blood pressure >150 mm Hg and/or
diastolic blood pressure >95 mm Hg) and glucose
>126 mg/dL. Complete blood count and chemistry panel,
estradiol, and FSH were performed at the clinical labora-
tories at each recruiting center. Lipid profiles and thyroid-
stimulating hormone (TSH) were performed at the Kronos
Science Laboratories (Phoenix, AZ, USA). At screening,
women were asked to rank their menopausal symptoms
(hotflashes, night sweats, vaginal dryness, dyspareunia,
palpitations, insomnia, depression, mood swings, and
irritability) as either none, mild, moderate, or severe.
Finally, all subjects were screened for CAC and women
with Agatston score ≥50 U, indicating significant subclin-
ical coronary artery disease, were excluded. All women
meeting inclusion criteria underwent baseline measure-
ments of CIMT by B-mode ultrasound [44]. All imaging
results are read centrally by individuals blinded to partic-
ipant demographics (CAC at the Los Angeles Biomedical
Research Institute at Harbor-UCLA, Torrance, CA, USA
under the direction of Dr. M. Budoff and CIMT at the
Atherosclerosis Research Unit Core Imaging and Reading
Center, University of Southern California, Los Angeles,
CA, USA under the direction of Dr. H. Hodis).
Analysis of variance was used to determine statistical
significance except where an alternative test is specified.
Statistical significance was accepted at P<0.05.
Recruitment and Enrollment into KEEPS
Subjects were recruited through nine clinical study centers
(Brigham and Women’s Hospital, Boston, MA, USA;
Columbia University College of Physicians and Surgeons,
New York, NY, USA; Mayo Clinic, Rochester, MN, USA;
Montefiore Medical Center, Bronx, NY, USA; Kronos
Longevity Research Institute, Phoenix, AZ, USA; Univer-
sity of California at San Francisco, San Francisco, CA,
USA; University of Utah School of Medicine, Salt Lake
City, UT, USA; University of Washington School of
Medicine; Tacoma, WA, USA; Yale University School of
Medicine, New Haven, CT, USA) beginning in July, 2005
with complete enrollment of 728 participants qualified for
randomization in June, 2008. Subjects were recruited using
a variety of strategies including mass mailings, recruiting
posters in hospitals and clinics, print and electronic
media advertisements, and an internet web page (www.
keepstudy.org).
Contacts were asked a series of standard questions from
a Phone Screen Interview Form. Of 4,533 phone enquiries,
2,528 callers were disqualified and 927 others, who were
qualified, either failed to make or show up for screening
visit appointments or did not complete screening for
personal reasons. Women who qualified by phone screen
gave written informed consent at their screening visit. Of
these 1,078 women, 290 candidates were excluded based
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imaging procedures (Table 1). Some subjects had more
than one disqualification factor (45 with two, seven with
three, and three with four exclusions). The major cardio-
vascular risk factor disqualifying women was a CAC score
>50 AU, which represented 3.7% of women qualified by
phone screen and 14.5% of disqualified women (Table 1).
The average level of education and income were greater
in women meeting eligibility criteria compared to those
women who were disqualified. Women who were disquali-
fied also were more likely to have never married or
declined to report marital status than women who were
qualified (Table 2). Menopausal symptoms scores were
similar between women excluded and those meeting
eligibility criteria (9.0±5.4, n=257 and 9.4±5.4, n=728,
respectively). Women meeting eligibility criteria were
younger, had lower LDL cholesterol, and had lower systolic
blood pressure than women excluded (Table 3).
CIMT in women subsequently disqualified from KEEPS
did not differ significantly from that of women meeting
eligibility requirements [0.725±0.084 mm (n=113) and
0.726±0.90 mm (n=718), respectively]. Repeat CIMT
readings on the same individual performed within 90 days
had a coefficient of variation between scan 1 and scan 2 of
less than 1% (0.84±0.99%; minimum of 0% and a
maximum of 11%).
Comparison of Demographics and Cardiovascular Risk
Factors of Women Enrolled into KEEPS with Those
in the WHI
Women qualified for KEEPS represent a similar ethnic mix to
women enrolled in the CEE+MPA arm of the WHI (Table 4).
However, women who qualified for KEEPS had higher
levels of education and more declined to report their income
level than women in the WHI (Table 2). The percentage of
women who qualified for KEEPS who report partnered/
separated and divorced status is similar to that reported in the
WHI with the exception that fewer women who qualified for
KEEPS reported a widowed status while more reported
never having been married. This finding may reflect the
difference of nearly a decade in mean ages of participants
between the two studies (Tables 2 and 3). Prior hormone use
did not differ between participants in KEEPS and WHI but
the incidence and severity of menopausal symptoms were
strikingly different, with 67% of KEEPS-qualified women
reporting severe symptoms compared to 61% of WHI
women reporting no symptoms. These differences were also
characteristic of women in the 50–59-year grouping of the
WHI with the exception of the number of participants that
were current hormone users and were higher in the WHI than
in women qualified for KEEPS (Table 2).
Table 1 Number of recorded reasons for disqualifications from
KEEPS by screening examination(s)
Number
History
Depression 3
Over age (>59 year) 1
LMP >3 year 6
Not menopausal 19
DES exposure in utero 3
Uterine ablation/hysterectomy 6
Cardiovascular disease 2
Medication or hormone use 14
Thromboembolic disease 2
History of cancer 2
HIV+ 1
Hypertension 4
Cerebrovascular disease 1
Gall bladder disease 0
Diabetes mellitus 3
Smoke >10 cig/day 1
Other history 7
Laboratory tests
E2 >40 pg/mL 62
FSH <35 ng/mL 24
LDL >190 mg/dL 30
Trig >400 mg/dL 2
Hypothyroid (TSH >5 mL U/L) 4
Hyperthyroid (TSH <0.2, fT4 >2 mL U/L) 3
Other 15
Physical examination
Hypertension (150/95) 4
BMI >35 mm
2/kg 11
Breast mass 3
Abnormal cardiovascular exam
a 2
Abnormal pelvic exam 5
Other PE finding 4
Other screening tests
CAC scan score >50 AU 42
CIMT scan abnormal 0
Transvaginal ultrasound >5 mm or abnormal 31
PAP smear abnormal 4
BDI score >17 (depressed) 10
MMSE score <23 (demented) 0
Mammogram abnormal 6
ECG abnormal
a 12
Endometrial aspirate abnormal 4
Other imaging/testing abnormal 5
LMP last menstrual period, DES diethylstilbestrol, BMI body mass
index, E2 17β-estradiol, FSH follicle-stimulating hormone, LDL low-
density lipoprotein, Trig triglycerides, CAC coronary arterial calcium,
AU Agatston units, CIMT carotid intima–media thickness, BDI Beck
Depression Inventory, MMSE minimental state examination, ECG
electrocardiogram
aEvidence of myocardial infarction, angina, or congestive heart failure
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about 50% less in qualified KEEPS participants than
women of the WHI. All other conventional cardiovascular
risk factors comprising the Framingham Risk Score
including systolic blood pressure, total cholesterol, and
HDL-C were significantly different between women meet-
ing eligibility for KEEPS and those in the WHI (Table 3).
The same was true of CVD risk factors not included in the
Framingham score such as BMI and fasting triglycerides
and glucose, reflecting a reduced 10-year CVD risk for
women in KEEPS compared to those in the WHI.
Conclusions and Future Directions
KEEPS is an example of a study that leveraged character-
istics of populations in observational and epidemiological
studies and incorporated design elements from basic
Table 2 Demographic characteristics of women screened and qualified for KEEPS compared to those enrolled in the WHI
KEEPS WHI (CEE+MPA)
a
Excluded Qualified All average age 63 (N=16,608) 50–59years (N=5,522)
N % N %% %
Education
Grade school 18 0.5 3 0.4 2.3 2.8
Some high school 35 0.9 3 0.4 4.5 3.9
High school or GED 166 4.4 52 7.1 19.5 16.5*
Some college/vocational 416 11.1 131 18.0 38.9 39.1*
College graduate or higher 1030 27.4 483 66.3 34.9 37.7*
Not answered 2091 55.7 56 7.7 ND ND
Income
b
<$10,000 48 1.3 5 0.7 5.5 6.5
$10 to <$20,000 85 2.3 10 1.4 15.0 10.2
$20 to <$ (35) 40,000 122 3.2 47 6.5 27.5 21.8
$(35) 40 to $(50) <60,000 177 4.7 77 10.6 21.2 20.6
$(50) 60 to $(75) <100,000 255 6.8 101 13.9 17.7 21.5
≥$(75) 100,000 266 7.1 122 16.8 13.2 19.4
Not answered 2803 74.6 366 50.3 ND ND
Marital status
Married/partnered 926 24.7 479 65.8 60.1 63.6
Separated/divorced 368 9.8 134 18.4 16.8 23.6
Widowed 60 1.6 19 2.6 19.0* 7.5
Never married 946 25.2 83 11.4 4.1 5.2*
Not answered 1454 38.7 13 1.8 ND ND
Smoking status
Never smokers ND ND 580 78.9 49.8 46.8*
MHT use
Never 78.7 73.4 70.5
Past 19.3 19.9 17.2
Current 1.9 7.7 12.3*
Menopausal symptoms
None 8 3.1 27 3.7 61.4 42.0*
Mild 76 29.6 203 27.9 26.2 35.6
Moderate to severe 173 67.3 498 68.4 12.4 22.4*
ND not determined or reported
*P<0.0001 (significantly different by chi-square test from KEEPS qualified participants)
aData derived from Annals of Epidemiology 13:S78–S86, 2003 [85]
bIncome for the WHI are reported as values in parentheses
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qualified for KEEPS are younger, healthier, reported more
menopausal symptoms, and have fewer cardiovascular risk
factors than women in the WHI. Therefore, women in
KEEPS more closely match the demographics of women in
observational studies. Although observational studies have
been criticized for reflecting a “healthy user bias” [72],
KEEPS is randomized and blinded so outcomes will not be
biased by participant group assignment. Also, KEEPS is
more representative of the typical clinical experience, i.e.,
women who are relatively healthy but who are experiencing
menopausal symptoms and who seek MHT around the time
of their menopausal transition.
One potential limitation of KEEPS is that the majority of
participantsareCaucasianandresultsmaynotbeapplicableto
diverse ethnic populations. However, as medicine moves
toward a pharmacogenomic approach to treatment choice,
personal definition of ethnicity may not be as relevant as a
genotypic definition. Alternatively, KEEPS may help to
define the subset of women for whom MHT may provide
the most favorable benefit/risk ratio. Furthermore, because a
large percentage of women in KEEPS are never smokers and
are otherwise at lower risk of CVD, as was the case in the
Estrogen for Prevention of Atherosclerosis Trial [44], KEEPS
results should more accurately reflect actions of MHT on
arteries less confounded by preexisting atherosclerosis as
was the case in the WHI. It might also be expected that as
KEEPS proceeds, various biochemical markers and soluble
cytokines known to be affected by estrogenic treatments will
show less variability among participants because fewer
participants are current smokers than in other studies.
Smoking is well recognized as a risk factor for CVD and
many of the components of tobacco smoke (particulate
matter, nicotine, carbon dioxide, oxygen-derived free radi-
cals, and other chemicals) negatively impact the same
biochemical pathways affected by estrogen [5, 63, 83, 96].
Ethnicity KEEPS cohort WHI
a
CEE+MPA all CEE+MPA 50–59years
Hispanic or Latino 7.3 5.3 8.9
Caucasian not Hispanic 70.5 84.0 77.0
African American alone 7.6 6.8 9.7
American Indian and Alaskan Native 0.3 0.3 0.5
Asian/Native Hawaiian/Pacific Islander 2.6 2.2 2.4
Other race or combination 1.0 ND ND
Unknown/not reporting 4.9 1.4 1.5
Table 4 Comparison of
race/ethnicity of
KEEPS participants with
that of participants
in WHI
Representation of race/ethnicity
as a percentage of entire cohort
ND not determined or reported
aData derived from Annals of
Epidemiology 13:S78–S86,
2003 [85]
Table 3 Comparison of conventional cardiovascular risk factors of participants in KEEPS with those of WHI participants randomized to
CEE+MPA
KEEPS WHI (CEE+MPA)
a
Excluded Qualified
N Mean ± SD N Mean ± SD Mean ± SD
Age 2,208 52.4±3.5 728 52.7±2.6*** 63.3*
BMI (kg/m
2) 235 26.7±4.6 722 26.2±4.3 28.5±5.4*
Systolic BP (mm Hg) 241 122.5±19.0 722 118.6±15.1*** 127.0±7.1*
Total cholesterol (mg/dL) 237 220±44 728 215±29 222±7*
LDL cholesterol (mg/dL) 236 134±37 728 129±29** 135±33*
HDL cholesterol (mg/dL) 240 64±18 728 65±18 55±14*
Triglycerides (mg/dL) 240 94±53 728 90±50 131±59*
Fasting glucose (mg/dL) 250 88.9±13.3 728 89.1±9.9 98.4±19.0*
aData derived from Annals of Epidemiology 13:S78–S86, 2003 [85]; for WHI—N=16,608 for age, BMI, and systolic BP, n=1319 for all other
parameters
BMI body mass index, BP blood pressure
*P<0.01 (statistical significance from qualified KEEPS participants); **P<0.05 (statistical significance from women excluded from KEEPS);
***P<0.01 (statistical significance from women excluded from KEEPS)
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challenging and the resultant socioeconomic and ethnicity
demographics of qualified participants reflect difficulties in
recruiting diverse groups of women. Negative reports in the
lay media that accompanied the scientific reporting of
results from the WHI scared many women away from use
of MHT, even those who were highly symptomatic. As in
observational studies where women most likely initiated
MHT for menopausal symptoms, the majority of women in
KEEPS reported moderate to severe menopausal symp-
toms, unlike the WHI in which symptomatic women were
discouraged from participation. It is in women seeking
treatment for symptoms that cardiovascular benefit has
been reported in observational studies. However, even in
the relatively asymptomatic women in the WHI, CAC
scores, an outcome of KEEPS, were significantly lower in
women between the ages of 50 and 59 years after 7 years of
blinded randomized to CEE compared to those receiving
placebo [58]. In the future, it will be important to better
understand biochemical and physiological differences be-
tween women with and without menopausal symptoms and
to clarify if even asymptomatic women would receive
benefit from MHT for chronic diseases of aging.
An unexpected finding from the KEEPS screening
processes was the number (nearly 4%) of women in this
age group, usually considered at low risk for CVD that had
to be excluded because of significant CAC, even in the
absence of other clinically significant cardiovascular risk
factors (i.e., elevated BMI and cholesterol, hypertension,
and diabetes). These observations are in agreement with
other studies and support the emerging concept that CAC
may be a common endpoint of multiple etiologies and may
be a sensitive indicator of atherosclerosis in middle-aged
humans [20, 21, 26, 54, 94]. As KEEPS continues, new
information will be gained regarding how MHT affects
progression of CAC and if the progression is related to
conventional risk factors or new biomarkers.
KEEPS will provide the first direct comparison of effects
of long-term use of oral versus transdermal MHT on
atherosclerosis in women. Such information is essential in
order for women to select treatments which best suit their
needs and lifestyle.
A major difference between KEEPS and studies in
experimental animals is that KEEPS participants underwent
natural menopause and not a surgical one. However, there are
now established animal models of ovarian failure which
should provide useful information about the similarities in
vascular actions of estrogen between types of menopause [4,
45]. Furthermore, data are emerging from observational
studies of women postovariectomy suggesting that MHT
reduces overall mortality and maintains cardiovascular health
and neurological function [3, 25, 29, 48, 51, 57, 67–70].
Prospective randomized trials are needed in this group of
women to validate the effectiveness of MHT for women
independent of the type of menopause [57]. In addition,
more information is needed about the type, dose, and
duration of progestogen therapies to reduce risk of uterine
cancer but still provide cardiovascular benefit [13]. Basic
science studies of the combined and pulsed use of
progestogens and vascular function are scarce [2, 55, 61, 93].
KEEPS has the advantage of being able to incorporate
mechanistic data from basic science studies which were not
available at the time of the design of the WHI. Therefore,
ancillary studies to the parent KEEPS protocol are ongoing
to examine new biomarkers of disease progression and
thrombotic risk [49, 50], genetic characterization of
estrogen receptors relative to response to MHT and
outcomes of KEEPS, measures of endothelial function,
and bone health which should provide prospective data to
complement data obtained from the WHI and Study of
Women Across the Nation [18, 56, 78–81, 90].
Finally, there are lessons to be learned from these
experiences of basic scientists and clinical investigators
involved in the study of cardiovascular actions of estrogen.
First, observational and epidemiological studies are hypothesis
generating and do not establish cause and effect. Second,
design of prospective clinical studies to test these hypotheses
should mimic, as closely as possible, the study population and
treatment circumstances of the observational studies. The
design should also take into account data from experimental
animals in which the basic information on drug action was
obtained without confounding variables. Separate studies may
be needed to account for such confounding variables (i.e.,
environmental pollutants, obesity, preexisting conditions like
diabetes). Third, the design should not compromise integrity of
primary outcomes for unrelated secondary outcomes. Fourth,
advancementsinunderstandingthebasicmechanismsofaction
of sex steroids was possible in the environment of sustained
funding by National Institutes of Health which attracted the
best scientists to tackle difficult questions. And finally,
collaboration among interdisciplinary teams will facilitate
translation of information from basic science to design of
clinical trials and ultimately improve the evidence upon which
to base clinical practice. These lessons may be considered
obvious and common sense, but are often overlooked.
The KEEPS is an example of a study that has incorporated
these lessons. KEEPS has matched its sample population to
that of observational studies, controlled for confounding
variables such as smoking and pre-clinical vascular disease,
and will evaluate a mode of treatment delivery similar to what
has been used in the majority of basic science studies.
Noninvasive measures of vascular health as outcomes also
will allow for analysis of disease progression and help to
support a paradigm shift in evaluating primary prevention [7].
Taking advantage of the latest technological advances in
imaging, diagnostics, and testing, KEEPS will provide
J. of Cardiovasc. Trans. Res. (2009) 2:228–239 235valuable information for women making decisions about
MHT and their health as they age [41]. The KEEPS cohort,
stored serum/plasma, and other data are valuable resources.
However, additional support from funding agencies will be
required in order to leverage these resources to address new
questions generated by KEEPS and to translate new
discoveries from basic science to further investigations of
this defined cohort.
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